ArticleScientific reports2025
Epidemiological characteristics of patients with invasive pulmonary aspergillosis infected with Aspergillus fumigatus from a tertiary hospital in Ningxia, China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Functional and molecular characterization ofJournal of medical microbiology · 2026Article
- Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.Journal of thoracic disease · 2026Article
- Exploring the Diversity and Distribution of Medico-Veterinary Fungal Diseases in Africa: Harnessing a Multisectoral One Health Strategy for Cost-Effective Prevention and Preparedness.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Invasive pulmonary aspergillosis (IPA) is a severe fungal infection primarily caused by Aspergillus fumigatus, representing a significant burden on public health. This study aims to address the limitations in the epidemiological characteristics, risk factors and diagnostic approaches for IPA by identifying clinical characteristics, laboratory findings, and chest CT imaging features that distinguish IPA from Aspergillus fumigatus colonization (AFC). We conducted a retrospective analysis of 249 hospitalized patients, including 77 with IPA and 172 with AFC, at Ningxia Medical University General Hospital from January 2018 to December 2023. Our findings revealed that patients with IPA exhibited higher rates of hemoptysis, dyspnea, and fever compared to those with AFC. Laboratory results indicated elevated levels of galactomannan (GM), white blood cell count (WBC), erythrocyte sedimentation rate (ESR), and platelet count in IPA patients. Chest computed tomography imaging studies showed higher incidences of cavity, consolidation, ground-glass opacity, and halo sign in IPA patients. Voriconazole was the primary treatment for 75.3% of IPA patients, who also had longer hospital stays and higher treatment costs. Multivariate logistic regression identified GM, ESR, chronic obstructive pulmonary disease (COPD), and hypertension as significant risk factors for IPA. Our study highlights the necessity of developing enhanced diagnostic models that integrate GM and ESR biomarkers to improve the specificity and sensitivity of IPA diagnosis. These findings provide valuable insights for early diagnosis and optimized treatment strategies, potentially improving patient outcomes and reducing healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.